A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,015

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Chronic Kidney Disease
Interventions
DRUG

Placebo

9g /day (3 times a day)

DRUG

AST-120

9g /day (3 times a day)

Trial Locations (106)

Unknown

Tuscaloosa

Hot Springs

Bakersfield

Glendale

Los Angeles

Palo Alto

Riverside

Denver

Boynton Beach

West Palm Beach

Augusta

Macon

Honolulu

Evergreen Park

Shawnee Mission

Kenner

Shreveport

Pontiac

Brooklyn Center

Flushing

Great Neck

New York

Williamsville

Elizabeth City

Cincinnati

Bend

Allentown

Doylestown

Lancaster

Providence

Charleston

Columbia

Orangeburg

Sumter

Knoxville

Nashville

Dallas

Houston

Arlington

Fairfax

Norfolk

Richmond

Suffolk

Vancouver

Morgantown

Milwaukee

Buenos Aires

Córdoba

San Miguel de Tucumán

Belo Horizonte

Botucatu

Campinas

Curitiba

Ibirapuera

Porto Alegre

Rio de Janeiro

São Paulo

Sorocaba

Calgary

Vancouver

Greenfield Park

Montreal

Hradec Králové

Liberec

Prague

Ústí nad Labem

Hamburg

Kiel

Mainz

Aguascalientes

Cuernavaca

Durango

Mexico City

México

Bialystok

Częstochowa

Lublin

Warsaw

San Juan

Arkhangelsk

Chelyabinsk

Kemerovo

Moscow

Novosibirsk

Orenburg

Petrozavodsk

Saint Petersburg

Saratov

Tomsk

Yaroslayl

Yekaterinburg

A Coruña

Asturias

Barcelona

Guadalajara

Madrid

Ivano-Frankivsk

Kharkiv

Kiev

Luhansk

Lviv

Mykolayiv

Poltava

Ternopil

Vinnitsa

Zaporizhzhya

Sponsors
All Listed Sponsors
collaborator

Kureha Corporation

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY